

**JOHNSON & JOHNSON**  
**SELECTED PHARMACEUTICALS IN LATE STAGE U.S. and E.U. DEVELOPMENT OR REGISTRATION**  
**As of April 16, 2013\***

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Acute Coronary Syndrome (2) Stent Thrombosis for Acute Coronary Syndrome (2)	FDA Second Complete Response 3/13 Re-Filed 9/12	
	INVOKANA™ (canagliflozin)	Type 2 diabetes (2) Fixed Dose Combination with Metformin (IR) (2) Fixed Dose Combination with Metformin (XR) (2)	Approved 3/13 Filed 12/12 Phase III	Filed 6/12 Filed 3/13
Immunology	STELARA® (ustekinumab)	Psoriatic Arthritis Crohn's Disease	Filed 11/12 Phase III	Filed 12/12 Phase III
	SIMPONI® (golimumab)	Rheumatoid Arthritis (IV)	Filed 9/12	File withdrawn, 12/12, resubmission pending Filed 7/12
		Ulcerative Colitis	Filed 7/12	
	sirukumab	Rheumatoid Arthritis	Phase III	Phase III
Infectious Diseases and Vaccines	SIRTURO™ (bedaquiline)	Multi-drug resistant tuberculosis (2)	Approved 12/12	Filed 8/12
	DORIBAX™ (doripenem)	Nosocomial Pneumonia (2)	FDA Complete Response letter 8/08 FDA Second Complete Response 10/10	Approved 7/08
	INCIVO® (telaprevir)	Chronic hepatitis C virus BID dosing (2)		Filed 1/13
	PREZISTA® (darunavir) and cobicistat (GS-9350)	Fixed Dose Combination HIV tablet for treatment naïve patients and treatment experienced patients	Phase III	Phase III
	simeprevir (TMC435)	Chronic hepatitis C virus (HCV) infection for treatment naïve patients (2)	Filed 3/13	Phase III
		Chronic hepatitis C virus (HCV) infection for treatment experienced patients, relapsers, and non-responders (2)	Filed 3/13	Phase III
Neuroscience	INVEGA® (paliperidone ER OROS)	Pediatric indication - adolescent schizophrenia	Approved 4/11	Filed 3/13
	INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate IM long acting injectable )	Schizophrenia - 3 month injectable (2)	Phase III	Phase III
Oncology	ibrutinib (PCI-32765)	Relapsed/refractory patients with Chronic Lymphocytic Leukemia (single agent) (2)	Phase III	Phase III
		Relapsed/refractory patients with Chronic Lymphocytic Leukemia (in combination with Bendamustine and Rituximab) (2)	Phase III	Phase III
		Treatment naïve patients with Chronic Lymphocytic Leukemia (single agent) (2)	Phase III	Phase III
		Refractory/relapsed patients with Mantle Cell Lymphoma (single agent) (2)	Phase III	Phase III
	VELCADE® (bortezomib)	Mantle Cell Lymphoma 1st line (2) Multiple Myeloma Transplant Multiple Myeloma Retreatment Multiple Myeloma Combination		Phase III Filed 4/12 Filed 9/12 Filed 10/12
	YONDELIS® (trabectedin)	Soft Tissue Sarcoma (2)	Phase III	
		Relapsed Ovarian cancer	Phase III	

\* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(2) Doribax™ developed in collaboration with Shionogi & Co., Invokana™ licensed from Mitsubishi Tanabe Pharma Corporation; Prezista®/cobicistat developed in collaboration with Gilead Sciences, Incivo® developed in collaboration with Vertex Pharmaceuticals Inc, Velcade® developed in collaboration with Millennium: The Takeda Oncology Company, Yondelis® developed in collaboration with PharmaMar, Xarelto® co-developed with Bayer HealthCare, Invega® Sustenna® developed in collaboration with Alkermes, Inc., simeprevir (TMC435) developed in collaboration with Medivir AB, ibrutinib (PCI-32765) developed in collaboration with Pharmacyclics and sirukumab developed in collaboration with GlaxoSmithKline.

*Johnson & Johnson*

# Johnson & Johnson

## Selected Pharmaceutical Pipeline - Recent Approvals/Potential Filings\*

Selective Highlights as of April 16, 2013

APPROVED 2012/2013	IN REGISTRATION	PLANNED FILINGS 2013-2015*
<p><b><u>2012</u></b></p> <p>DACOGEN® (EU) (decitabine) Oncology</p> <p>SIRTURO™ (US) (bedaquiline) Infectious Diseases &amp; Vaccines</p> <p><b><u>2013</u></b></p> <p>INVOKANA™ (US) (canagliflozin) Cardiovascular &amp; Metabolism</p>	<p>SIRTURO™ (EU) (bedaquiline) Infectious Diseases &amp; Vaccines</p> <p>Simeprevir (TMC 435) (US) Infectious Diseases &amp; Vaccines</p> <p>INVOKANA™ (EU) (canagliflozin) Cardiovascular &amp; Metabolism</p>	<p>Ibrutinib (PCI-32765) Oncology</p> <p>Siltuximab (CNTO 328) Oncology</p> <p>Simeprevir (TMC 435) (EU) Infectious Diseases &amp; Vaccines</p>

\* Filings/approvals assumed to be in US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

DACOGEN® developed in collaboration with Eisai Corporation of North America;; INVOKANA™ developed in collaboration with Mitsubishi Tanabe Pharma Corporation; Simeprevir (TMC435) developed in collaboration with Medivir AB.; Ibrutinib is being developed in collaboration with Pharmacyclics, Inc.